What Would the CVS/Aetna Merger Mean for Healthcare?

Despite the uncertainty surrounding the industry, healthcare mergers and acquisitions, like the proposed CVS Health/Aetna deal, continue to occur. Healthcare is leading other industries in high-grade M&A activity and, according to a PwC report, the health care industry has initiated more than 200 deals per quarter for 12 straight quarters since 2015.

If the CVS and Aetna deal is approved, the acquisition will be the largest healthcare insurance deal on record based on Aetna’s market capitalization. How could this impact the healthcare industry as a whole? Bruce Carver, associate vice president of payer services, recently connected with Managed Healthcare Executive to share his thoughts. Here are three key implications outlined from the discussion:

  • Impact on Industry Competition – If the merger is approved, healthcare executives will likely need to rethink traditional industry competitors as this would establish market competition against national payer UnitedHealth Group and its ownership of OptumRx.
  • Greater Transparency From Pharmacy Benefit Managers (PBMs) – PBMs have historically been viewed as the drug purchasing middlemen to negotiate lower prices. However, questions have arisen as to whether the savings have actually been passed on to employers and/or consumers. As a result, the market is demanding more pricing transparency. New integrated models, similar to the one created by the CVS and Aetna merger, will help facilitate that transparency.
  • Give Employers and Consumers More Control – By allowing employers and consumers to own more of their healthcare and pharmacy benefits, the industry could save millions. For example, by creating pharmacy benefits that incentivize people with chronic conditions (e.g. diabetes, high blood pressure) to fill and adhere to their medications, the industry could prevent avoidable hospital admissions that cost over $100 billion a year. An integrated insurer, like CVS and Aetna, could establish such incentives.

To read more insights from Bruce, and other industry experts, check out the full Managed Healthcare Executive articles here and here. If you’re looking for a partner to help your organization manage the shifting healthcare landscape, contact us here.

Posted in

MedeAnalytics

MedeAnalytics is a leader in healthcare analytics, providing innovative solutions that enable measurable impact for healthcare payers and providers. With the most advanced data orchestration in healthcare, payers and providers count on us to deliver actionable insights that improve financial, operational, and clinical outcomes. To date, we’ve helped uncover millions of dollars in savings annually.

Leave a Comment





Get our take on industry trends

Providers: Are you ready to be audited?

February 15, 2022

By Donna Kennedy In 2020, regular audits conducted by CMS and other payers were paused or significantly reduced as the…

Read on...

From Insights to Action – The Digital Transformation of Healthcare in the Post-Pandemic “New Normal”

February 10, 2022

In November, MedeAnalytics hosted the 2021 Impact Summit, an engaging and educational event held annually and designed exclusively for our…

Read on...
From Insights to Action – The Digital Transformation of Healthcare in the Post-Pandemic “New Normal”

2022 Rx: Your new, post-pandemic prescription for success

January 11, 2022

By Dave Schweppe, Chief Analytics Officer, MedeAnalytics Despite the common use of the term “post-COVID,” most leaders across the healthcare…

Read on...
Combating the opioid epidemic photo

Combating the opioid epidemic in North America with Nobel Prize winning research

October 12, 2021

American Researchers Dr. David Julius and Dr. Ardem Patapoutian from California were awarded the Nobel Prize in medicine for their path breaking work on the development of non-opioid painkillers, showing immense promise for combating the epidemic.

Read on...